SCHEMBL20178641

SCHEMBL20178641

CCN1CCc2cc(C(=O)O)ccc2C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.51
HRH3 Q9Y5N1 2/20 0.46
POLB P06746 1/20 0.44
ITGB3 P05106 2/20 0.44
ITGA2B P08514 2/20 0.44
DRD2 P14416 2/20 0.43
DRD1 P21728 1/20 0.43
AKR1C3 P42330 3/20 0.43
LTA4H P09960 1/20 0.43
PNMT P11086 1/20 0.43
ACACB O00763 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
NAMPT P43490 1/20 0.43
MYC P01106 1/20 0.42
HTR1A P08908 1/20 0.42
HTR2A P28223 1/20 0.42
SLC6A4 P31645 1/20 0.42
HTR7 P34969 1/20 0.42
HRH1 P35367 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3604547 0.88 ALDH1A1 (0.49) ALDH1A1DRD2PNMTNAMPTHTR1A
SCHEMBL20178702 0.87 NAMPT (0.52) ALDH1A1POLBHDAC8HDAC6NAMPT
SCHEMBL7788367 0.85 ITGB3 (0.58) ALDH1A1POLBITGB3ITGA2BDRD2
SCHEMBL10120332 0.84 HDAC6 (0.62) HDAC8HDAC6
SCHEMBL20178679 0.84 ACACB (0.59) ALDH1A1HRH3ACACBHDAC8HDAC6
SCHEMBL27490478 0.83 ALDH1A1 (0.49) ALDH1A1POLBITGB3ITGA2BAKR1C3
SCHEMBL27774602 0.82 ALDH1A1 (0.49) ALDH1A1ITGB3ITGA2BDRD2AKR1C3
SCHEMBL4239488 0.81 MEN1 (0.61) ALDH1A1POLBLTA4HHDAC6HTR1A
SCHEMBL3350732 0.80 DRD2 (0.59) ALDH1A1DRD2LTA4HMYCHTR1A
SCHEMBL3313430 0.80 ALDH1A1 (0.61) ALDH1A1DRD2DRD1AKR1C3HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 ALDH1A1 2185/4885HRH3 582/4885POLB 3868/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 ALDH1A1 2185/4885HRH3 582/4885POLB 3868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.